

15 AUGUST 2026



Notification of changes to Bupa separately chargeable drugs list

This bulletin aims to keep you up-to-date with any changes to the Bupa Separately Chargeable Drugs List.

To ensure you are always viewing the latest version of the list, please refer to the electronic copy found at www.bupa.co.uk/healthcare-professionals/pol-latest-updates

The revised list comes into effect this month and includes additions to the list, as shown on the table below.

The list now also includes details of the available preparations of each drug and the codes to be used when invoicing for the drug.

Regular updates to the list will be issued, so it is important to always ensure that you are using a valid version. By accessing the list electronically at www.bupa.co.uk/healthcare-professionals/pol-latest-updates you can be confident that it is up-to-date.

If you have any questions, please call Bupa Provider Services on **0345 755 33 33**. Lines are open 9am to 5pm, Monday to Friday. Calls may be recorded and may be monitored.

Thank you

Dr Tim Woodman
Medical Director, Policy and Cancer Services, Bupa UK Insurance

Drugs added:

Code	Code narrative	Effective Date	Comments
AE177	Mirvetuximab soravtansine (Elahere) 5 mg/mL (100mg/20ml) concentrate for solution for infusion	12/08/2025	
AE178	Luspatercept (Reblozyl) 25mg powder for solution for injection	12/03/2024	
AE179	Pembrolizumab (Keytruda) 395 mg Solution for injection	01/02/2026	

Drugs removed:

No Changes this month

Drugs amended:

Code	Code narrative	Effective Date	Comments
AE087	Faricimab (Vabysmo) 28.8mg/ 0.24mL Inj	28/07/2026	Previous narrative Vabysmo (Faricimab) 120mg/ml - 6mg vial for injection